Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
Immunotherapy Advances · 01.01.2022 · 2 (1)
DOI: 10.1093/immadv/ltac005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 25.01.2022. Verfasst von Rafaela Rossetti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell-Based Therapy, Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: São Paulo Research Foundation, National Council of Technological and Scientific Development, Coordination for the Improvement of Higher Education Personnel.
Abstract (Originalsprache)
Immune checkpoint (IC) blockade using monoclonal antibodies is currently one of the most successful immunotherapeutic interventions to treat cancer. By reinvigorating antitumor exhausted T cells, this approach can lead to durable clinical responses. However, the majority of patients either do not respond or present a short-lived response to IC blockade, in part due to a scarcity of tumor-specific T cells within the tumor microenvironment. Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) provide the necessary tumor-specific immune cell population to target cancer cells. However, this therapy has been considerably ineffective against solid tumors in part due to IC-mediated immunosuppressive effects within the tumor microenvironment. These limitations could be overcome by associating adoptive cell transfer of genetically engineered T cells and IC blockade. In this comprehensive review, we highlight the strategies and outcomes of preclinical and clinical attempts to disrupt IC signaling in adoptive T-cell transfer against cancer. These strategies include combined administration of genetically engineered T cells and IC inhibitors, engineered T cells with intrinsic modifications to disrupt IC signaling, and the design of CARs against IC molecules. The current landscape indicates that the synergy of the fast-paced refinements of gene-editing technologies and synthetic biology and the increased comprehension of IC signaling will certainly translate into a novel and more effective immunotherapeutic approaches to treat patients with cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cell-Based Therapy, Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
- Biotechnology Nucleus - Blood Center of Ribeirão Preto, Butantan Institute, São Paulo, Brazil.
ORCID-Profile: Lucas Eduardo Botelho de Souza
Förderung
- São Paulo Research Foundation
- National Council of Technological and Scientific Development
- Coordination for the Improvement of Higher Education Personnel
Zitieren
APA
Rossetti, R., Brand, H., Lima, S. C. G., Furtado, I. P., Silveira, R. M., Fantacini, D. M. C., Covas, D. T., & de Souza, L. E. B. (2022). Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy Advances, 2(1). https://doi.org/10.1093/immadv/ltac005
Vancouver
Rossetti R, Brand H, Lima SCG, Furtado IP, Silveira RM, Fantacini DMC, et al. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy Advances. 2022;2(1). doi:10.1093/immadv/ltac005
BibTeX
@article{Rossetti2022,
author = {Rossetti, Rafaela and Brand, Heloísa and Lima, Sarah Caroline Gomes and Furtado, Izadora Peter and Silveira, Roberta Maraninchi and Fantacini, Daianne Maciely Carvalho and Covas, Dimas Tadeu and de Souza, Lucas Eduardo Botelho},
title = {Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer},
journal = {Immunotherapy Advances},
year = {2022},
volume = {2},
number = {1},
doi = {10.1093/immadv/ltac005}
}
EUVIMED